The role of low-density lipoprotein cholesterol (LDL-C) in the evolution of heart disease is fairly well established. In addition, the benefits of pharmacological treatment with agents that lower LDL-C in high-risk patients are well documented. Lipoproteins are biochemical structures that enable the transport of lipids such as cholesterol in the circulation. LDL-C represents the amount … Read more
There are several reasons why we should be interested in the amount of cholesterol circulating in our bloodstream. However, to interpret our cholesterol numbers, we have to know certain things about cholesterol and its role in health and disease. What Is Cholesterol? Cholesterol is classified as a sterol (a combination of steroid and alcohol) and … Read more
The eagerly awaited results of the FOURIER trial were recently presented at the Annual Meeting of the American College of Cardiology (ACC) in Washington DC and simultaneously published in the New England Journal of Medicine (1). The goal of FOURIER was to evaluate the efficacy and safety of evolocumab (Repatha), a PCSK9 inhibitor, among subjects with elevated risk … Read more
Cholesterol-lowering medications are being prescribed to almost 30% of US adults aged 40 and over, most of these are statins drugs (1). The number increases with age, and approximately 48% of adults older than 75 are receiving such treatment. It has been suggested that treating more older individuals with statins may prevent a substantial number of cardiovascular events, and that, … Read more
The results from the recent GLAGOV trial suggest that aggressive lowering of LDL-cholesterol with a PCSK9-inhibitor on top of statin therapy in patients with coronary artery disease may reduce atherosclerotic plaque burden. Although these results provide support for the lipid hypothesis and may have significant implications for the future of cardiovascular medicine, our eyes are still on safety and … Read more
